Viva Biotech Holdings · HKEX:1873
Viva Biotech — H1 2024 Earnings Presentation
31 slides from Viva Biotech's earnings presentation, Aug 30, 2024
Slide 1: Viva Biotech 2024 Interim Results
Viva Biotech 2024 Interim Results 30 August 2024
Slide 2: Forward-Looking Statements; Non-IFRS
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
Viva PART 1: Business Highlights
Slide 5: World Leading One-stop Innovative Original Drug R&D and Production Platform
World Leading One-stop Innovative Original Drug R&D and Production Platform CDMO Research and EFS Investment and CRO Business Production Business Incubation Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core
Slide 6: Equity Structure of Viva Biotech
Equity Structure of Viva Biotech Viva Biotech Holdings (1873.HK) 10.87% Strategic investors 26.34% 73.66% 100% 100% Small Molecule Incubator CRO CDMO 100% 100% 100% Incubators Onshore Equity Offshore Equity Shanghai Jiaxing Suzhou Chengdu Overseas Shanghai Ningbo Taizhou Holding Platform Holding Pla
Slide 7: Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services
Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services Affinity-Based Drug Screening Mass Spectrometry (ASMS, INTACT-MS) SPR Drug Metabolism Crystal Soaking (ADME/DMPK) Protein Science and V-DEL Structural Research Compound Library (Covalent Compounds, Pharmacology Platfo
Slide 8: Overview
Overview Business Highlights Revenue RMB million Revenue in 2024H1 reached RMB 981.8 million, -14.0% YOY Gross profit reached RMB 339.1 million, -16.5% YOY Adjusted net profit reached RMB 168.2 million, +15.1% YOY Adjusted Earnings per Share (EPS) of RMB 0.06 As of the end of the period, t
Slide 9: Overview: CRO Business
Overview CRO Business: Expected to Gradually Recover in Future Despite Fluctuations in Short-term Growth Revenue: RMB 385.9 million, -12.5% YOY Gross Profit: RMB 167.2 million, -15.5% YOY 54.1 12.3 Top 10 Customer Revenue Contribution: 25.7% Revenue from Overseas Clients: 88.8%, decreased by
Slide 10: CRO Business: Cost Reduction, Efficiency Improvement and Client Growth
CRO Business: Continuous Cost Reduction and Efficiency Improvement, and Steady Growth in Client Numbers Continued Optimization of CRO R&D Personnel, driving Served Top 50 Global Ongoing Cost Reduction and Efficiency Improvement Pharmaceutical Companies 2024H1 1117 2023 1155 2023H1 1341 Based on Tota
Slide 11: CRO Business: Target and Protein Structure Deliveries
CRO Business: Steady Operations with Continued Increase in Target and Protein Structure Deliveries Radiation Source Usage Hours Number of Target and Protein Structure Deliveries 2024H1 873 2023 2059 Independent Target Research: +79 YoY 2023H1 1020 Maintaining long-term cooperation with 13 global
Slide 12: AI Technology Driven Experiments Pave the Way for a New Era in Drug Development
AI Technology Driven Experiments Pave the Way for a New Era in Drug Development Target Hit Compound Lead Compound Safety and Efficacy Identification Identification Optimization Evaluation AI Structure Prediction Virtual Screening and Free Energy Perturbation ADME/PK Molecular Generation Property Pre
Slide 13: Overview: CDMO R&D and Production Services
Overview CDMO R&D and Production Services Revenue of Langhua: RMB 595.9 million, -15.0% YOY 141 Adjusted Gross Profit of Langhua: RMB 179.0 million, -16.8% YOY CDMO: Revenue RMB 338.9 million, -18.7% YOY; adjusted gross profit margin 131 143 40.7%, +1.6pp YOY 126 API: Revenue RMB 126.0 milli
Slide 14: CDMO Business: Front-end Funnel Effect and Capacity Building
CDMO Business: The Front-end Funnel Effect Continues to Manifest, while Capacity Building Continues to Advance Revenue and Gross Profit from CDMO RMB million 416.9 338.9 163 137.8 2023H1 2024H1 Revenue Adjusted gross profit margin Revenue from CDMO: RMB 338.9 million，decreased by 18.7% YOY; the de
Slide 15: Langhua Factory's Capacity Building Status
Langhua Factory’s Capacity Building Status: Production Capacity Expansion Plan (2024-2026E) Cubic metre 2026E 1260 2025E 1260 (Expected to enter pilot production as early as 2025Q4) 2024 860 C 1 A1 B 1 In addition, Langhua Pharmaceutical plans to establish a new capacity of 400 cubic meters betwee
Slide 16: Constant Increase in the Number of CMC Projects
Constant Increase in the Number of CMC Projects Enhancing Internal Efforts to Channel Resources Revenue Scale RMB CMC R&D Staff ~RMB56 million 2024H1 117 2023 113 2023H1 129 ~RMB23 million ~RMB21 million Historical Trends in the Cumulative Number of CMC Projects 2024H1 218 2023H1 2023 2024H1 2023 18
Slide 17: Overview: EFS Investment & Incubation Business
Overview EFS Investment & Incubation Business RMB million As at June 30, 2024, the Group had invested in a total of 92 portfolio companies. 1369 1309 1290.3 During the reporting period，several portfolio companies achieved partial exits, which successfully realized the corresponding investment in
Slide 18: VBI Investment Exits and Components Overview
VBI Investment Exits and Components Overview In 2024H1，VBI has invested in a total of 92 portfolio companies. In 2024H1， the Company achieved partial investment exits from several incubation portfolio companies, successfully realized investment income and received cash of approx. RMB 144.1 milli
Slide 19: Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress
Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress • Boehringer Ingelheim acquired Nerio 222 Pipeline Projects in Portfolio Companies Therapeutics in a deal valued up to US$1.3 billion for new immune checkpoint inhibitors. *Calculated Based on the Cumulative Number of Portfolio C
Slide 20: Key Projects in VBI Investment Portfolio
Key Projects in VBI Investment Portfolio No. Name Country Mechanism Indication Pipeline Company Overview Dogma has discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical Small Metabolic species. Guided by dozens of high-resolution x-
Slide 21: Part 2: Financial Performance
PART 2: Financial Performance
Slide 22: Financial Performance of the Group
Financial Performance of the Group Revenue of the Group RMB million Adjusted Gross Profit RMB million 1142.2 981.8 413.1 346.2 2023H1 2024H1 2023H1 2024H1 Adjusted Net Profit Experienced a YOY Increase RMB million Adjusted EBITDA Experienced a YOY Increase RMB million Increased 13.1% Increased 15.1%
Slide 23: CRO Financial Statistics
CRO Financial Statistics CRO Revenue RMB million Adjusted Gross Profit RMB million 441.3 385.9 198 167 2023H1 2024H1 2023H1 2024H1 No. of CRO R&D personnel Annual revenue per CRO Personnel RMB’000 Increased 5.0% 1341 1117 658.2 691 2023H1 2024H1 2023H1 2024H1 www.vivabiotech.com 23
Slide 24: CDMO Financial Statistics
CDMO Financial Statistics Revenue of Langhua Pharmaceutical RMB million Adjusted Gross Profit of Langhua Pharmaceutical RMB million 700.9 595.9 215.2 179.0 2023H1 2024H1 2023H1 2024H1 www.vivabiotech.com 24
Slide 25: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities As at June 30, 2024 CDMO and Drug discovery services VBI Total commercialization services Types of goods or services RMB’000 RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 286,886 - - 286,886 Fee-for-service (FFS) 69,383
Slide 26: Items Measured at Fair Value with Changes Recognized in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows ： RMB’000 January 1, 2024 995,281 Acquired 8,769 Recognized from SFE revenue 2,533 Gain on fair value chan
Slide 27: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2024H1 2023 2023H1 2022 2022H1 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit / (Loss) 144,237 -99,790 13,659 -504,220 -85,220 Add: Fair Value Gain on Financial Liabilities at FVTPL -174,323 -10,050 -10,050 Add: interest expenses of the debt components of t
Slide 28: Part 3: Future Strategies
Viva PART 3: Future Strategies
Slide 29: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To Establish an Open and Cooperative Platform and a Early-stage Win-win Ecosystem for Global Biopharmaceutical Innovators preclinical service Raise technology barriers and expand servic
Slide 30: Q&A Session
Viva Q&A Session
Slide 31: Viva Biotech Holdings
Viva Biotech Holdings No.735, Ziping Road, Pudong New Area, Shanghai 201318, China —— Tel: +86 21 6089 3288 E-mail: info@vivabiotech.com www.vivabiotech.com
Viva Biotech Holdings — H1 2024 Earnings Presentation on 6ix